Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Jan 13, 2025
- Accession no.
- 0001601830-25-000010
- Filed
- Jan 13, 2025
- Trade date
- Jan 8-10, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $287.2K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 8, 2025 | Class A Common Stock | CConversionAcquired | +20,000 | $0.00 | $0 | 756,633 | Direct | |
| Jan 8, 2025 | Class A Common Stock | SSaleDisposed | −20,000 | $7.31 | −$146,200 | 736,633 | Direct | |
| Jan 10, 2025 | Class A Common Stock | CConversionAcquired | +20,000 | $0.00 | $0 | 756,633 | Direct | |
| Jan 10, 2025 | Class A Common Stock | SSaleDisposed | −20,000 | $7.05 | −$141,000 | 736,633 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 8, 2025 | Class A Common Stock | CConversionDisposed | −20,000 | $0.00 | $0 | 5,996,700 | Direct | |
| Jan 10, 2025 | Class A Common Stock | CConversionDisposed | −20,000 | $0.00 | $0 | 5,976,700 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.